Close Menu

NEW YORK (GenomeWeb) – Investment bank Jefferies today initiated coverage of the stock of transplant diagnostics firm CareDx with a Buy rating and a price target of $35.

In a note to investors, Jefferies analyst Brandon Couillard said that the company is well positioned as a leader in the transplant diagnostics market — which he estimated at more than $2 billion — with two tests on the market that serve an unmet need for non-invasive detection of heart and kidney post-transplant rejection.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.